Skip to content

You can have confidence in your biosimilar medicines

Learn more
Switching to biosimilars is safe and effective for patients
Learn more
Previous
Next

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.

Resources

Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

Manitoba Announces Transition to Cost-Saving Biosimilar Medicines

All Ten Canadian Provinces Have Now Made the Switch to Biosimilars Toronto – August 6, 2024 – Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, welcomes the announcement by the Government of Manitoba that it has implemented a...
Read more

B.C.’s biosimilar initiative saves money, reinvests to expand drug coverage

Over the first five years of the initiative, the Province saved $732 million, thanks to people transitioning from reference biologics to their cost-effective biosimilars, which are highly similar versions of high-cost biologic drugs used to treat health concerns, such as diabetes, inflammatory conditions and certain cancers. 

Read more

Biosimilars Canada Announces Re-Election of Board Chair and Vice-Chair

Toronto – May 7, 2024 – Biosimilars Canada is pleased to announce the unanimous re-election of Mr. Mike Woolcock, Senior Vice President of Biosimilars and Specialty Products with Apotex, as Chair of the Biosimilars Canada Board. Mr. Mike Casia, President...
Read more